Samantha L. Shterengarts

Array ( [id] => 16842859 [patent_doc_number] => 11014933 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-25 [patent_title] => Non-peptide opioid receptor modulators [patent_app_type] => utility [patent_app_number] => 16/726420 [patent_app_country] => US [patent_app_date] => 2019-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 20 [patent_no_of_words] => 16082 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16726420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735619 [patent_doc_number] => 10961255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Imidazoles as histone demethylase inhibitors [patent_app_type] => utility [patent_app_number] => 16/722554 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30088 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16722554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925189 [patent_doc_number] => 11046650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Deuterated compounds and uses thereof [patent_app_type] => utility [patent_app_number] => 16/720645 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 35944 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16720645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16877953 [patent_doc_number] => 11028086 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Pyrido-imidazo rifamycins [patent_app_type] => utility [patent_app_number] => 16/718634 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 41 [patent_no_of_words] => 10062 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16718634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815336 [patent_doc_number] => 11420934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => PPAR agonists [patent_app_type] => utility [patent_app_number] => 16/715711 [patent_app_country] => US [patent_app_date] => 2019-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 57 [patent_no_of_words] => 37310 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16715711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768781 [patent_doc_number] => 20200115408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => TREHALOSE ANALOGUES [patent_app_type] => utility [patent_app_number] => 16/714017 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16635222 [patent_doc_number] => 10913717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof [patent_app_type] => utility [patent_app_number] => 16/706695 [patent_app_country] => US [patent_app_date] => 2019-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 9971 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16706695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735546 [patent_doc_number] => 10961181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Cationic lipids for therapeutic agent delivery formulations [patent_app_type] => utility [patent_app_number] => 16/700304 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 20236 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735546 [patent_doc_number] => 10961181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Cationic lipids for therapeutic agent delivery formulations [patent_app_type] => utility [patent_app_number] => 16/700304 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 20236 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735546 [patent_doc_number] => 10961181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Cationic lipids for therapeutic agent delivery formulations [patent_app_type] => utility [patent_app_number] => 16/700304 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 20236 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421876 [patent_doc_number] => 20200347074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/700200 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735546 [patent_doc_number] => 10961181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Cationic lipids for therapeutic agent delivery formulations [patent_app_type] => utility [patent_app_number] => 16/700304 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 20236 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18384469 [patent_doc_number] => 11655238 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => MMPL3 inhibitors, compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 17/295227 [patent_app_country] => US [patent_app_date] => 2019-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25421 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 223 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343556 [patent_doc_number] => 20220009887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/294808 [patent_app_country] => US [patent_app_date] => 2019-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090347 [patent_doc_number] => 20200199160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => STAT3 DIMERIZATION INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/685461 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134752 [patent_doc_number] => 11136298 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Method for producing fullerene derivative [patent_app_type] => utility [patent_app_number] => 16/680570 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7276 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17363519 [patent_doc_number] => 11230534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => KDM1A inhibitors for the treatment of disease [patent_app_type] => utility [patent_app_number] => 16/672083 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 65099 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16672083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828471 [patent_doc_number] => 20200129517 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => COMBINATION THERAPY FOR TREATMENT OF HEMATOLOGICAL DISEASES [patent_app_type] => utility [patent_app_number] => 16/670289 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18127910 [patent_doc_number] => 11554105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment [patent_app_type] => utility [patent_app_number] => 16/670218 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 38 [patent_no_of_words] => 21213 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236714 [patent_doc_number] => 20200253948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => CANNABINOID RECEPTOR AGONISTS AND SERINE HYDROLASE ENZYME INHIBITOR BASED ANXIOLYTIC THERAPEUTIC PRODUCT [patent_app_type] => utility [patent_app_number] => 16/670679 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670679 [rel_patent_id] =>[rel_patent_doc_number] =>)